Tesamorelin vs sermorelin: molecular differences
Similar names are a poor classification system. The structures explain the family resemblance; the clinical records give each compound its own history.
Full-length and shortened GHRH
The clinical pharmacology review describes tesamorelin as a stabilized analogue of full-length GHRH(1-44). Sermorelin consists of GHRH(1-29). Both preserve a portion of the natural hormone that can stimulate the pituitary’s GHRH receptor.
Tesamorelin also carries a trans-3-hexenoic acid addition at its N-terminus, the beginning of the peptide chain. That addition confers resistance to DPP-IV cleavage. Sermorelin lacks that protection. I enjoy this degree of chemical specificity: “growth hormone peptide” would erase the very difference the designers worked on.
Clinical comparisons
The clinical records are uneven. Tesamorelin has the pivotal visceral-fat trial in adults with HIV, a 52-week program, and the 2026 synthesis of five randomized trials. Sermorelin lacks a comparable body of visceral-fat trials.
No published head-to-head trial establishes which compound is superior. I give tesamorelin the stronger claim for its studied HIV-associated fat indication because that claim has direct clinical results behind it. That judgment offers no shortcut to choosing either compound for a different goal.
Ipamorelin and CJC-1295
The comparisons often expand to tesamorelin, ipamorelin and CJC-1295. Tesamorelin and CJC-1295 follow the GHRH route; ipamorelin belongs to the ghrelin-receptor secretagogue group. Related human physiology experiments used GHRH and GHRP-2 to examine distinct controls on GH secretion. Another experiment examined their responses during induced sex-hormone depletion. These are studies of hormone regulation, rather than trials establishing the benefits of a peptide combination.
The pivotal tesamorelin studies tested tesamorelin alone. There is no published human co-administration trial of tesamorelin with sermorelin, ipamorelin or CJC-1295 in this clinical record. I distrust a mixture claim assembled from each ingredient’s individual reputation.
Incretin pathways and urine assays
Tesamorelin stimulates pituitary growth-hormone release, followed by IGF-1 production, as shown in the healthy-men experiment. GLP-1 medicines act through a gut-hormone pathway affecting appetite, glucose and gastric emptying. These are distinct pharmacological classes.
Sport puts tesamorelin and related GHRH analogues in a prohibited group. The urine-analysis paper developed a method to screen for and confirm several of them together. A shared analytical method is an elegant response to related chemistry. Each compound still needs its own clinical record.